NasdaqGM:ORKABiotechs
Is Oruka Therapeutics’ (ORKA) ESOP Shelf Registration Quietly Redefining Its Funding Playbook?
Oruka Therapeutics, Inc. recently reported fourth-quarter 2025 results showing a net loss of US$29.58 million and a full-year 2025 net loss of US$105.43 million, alongside narrowing quarterly loss per share from continuing operations to US$0.45.
On the same day, the company filed a US$115.44 million shelf registration for 3,354,715 ordinary shares tied to an ESOP-related offering, highlighting its focus on funding flexibility while advancing mid-stage trials for ORKA-002 in psoriasis and...